Thuja et al. invest €1.8m in FabPulous

Health Innovation Fund, Limburg Ventures and Limburg investment company Industriebank LIOF also took part in the round, alongside other new, undisclosed investors.

FabPulous will use the fresh capital to commercialise its H-FABP (Heart Fatty Acid Binding Protein, FABP-3) True Rapid Test product, which is designed to determine a patient's risk level when it comes to a possible heart attack.

Previous funding
FabPulous's series-A round took place in January 2010. The company received funding from Thuja, Health Innovation, LIOF and Limburg.

Company
Founded in 2008 and headquartered in Maastricht, FabPulous is a developer of medical devices designed to assess a patient's risk level when it comes to a possible heart attack.

Its H-FABP True Rapid Test is disposable and designed to provide an accurate result within five minutes.

People
Diederik Engbersen is the CEO of FabPulous.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Benelux
• Healthcare
• Early-stage
• Netherlands